NCT02618187View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2016

Primary Completion Date

December 6, 2017

Study Completion Date

January 26, 2018

Conditions

Ulcerative Colitis

Interventions

DRUG

SER-287

DRUG

Placebo

DRUG

Placebo Pre-Treat

DRUG

Vancomycin Pre-Treat

Trial Locations (1)

01752

Community Clinical Research Network, Marlborough

All Listed Sponsors

lead

Seres Therapeutics, Inc.

INDUSTRY

NCT02618187 - A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis | Biotech Hunter | Biotech Hunter